

DMD#2600

IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES
EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER

Miki Katoh, Tomohito Matsui, Miki Nakajima, Chise Tateno, Yoshinori Soeno, Toru Horie,
Kazuhide Iwasaki, Katsutoshi Yoshizato and Tsuyoshi Yokoi

Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa
University (*M.K., T.M., M.N., T.Y.*), Kanazawa, Japan, Hiroshima Prefectural Institute of
Industrial Science and Technology, Cooperative Link of Unique Science and Technology for
Economy Revitalization (*C.T., K.Y.*), Hiroshima, Japan, PhenixBio, Co., Ltd. (*Y.S., T.H.*),
Hiroshima, Japan, Pfizer Japan, Ltd. (*K.I.*), Aichi, Japan, and Graduate School of Science,
Hiroshima University (*K.Y.*), Hiroshima, Japan.

DMD#2600

Running title: Induction of human CYPs in chimeric mice in vivo.

To whom all correspondence should be sent:

Tsuyoshi Yokoi, Ph.D.

Drug Metabolism and Toxicology

Division of Pharmaceutical Sciences

Graduate School of Medical Science

Kanazawa University

Kakuma-machi

Kanazawa 920-1192, Japan

Tel / Fax: +81-76-234-4407

E-mail: TYOKOI@kenroku.kanazawa-u.ac.jp

This manuscript consists of 31 pages of text, 3 tables, 8 figures and 38 references.

Abstract: 234 words

Introduction: 621 words

Discussion: 1500 words

¹Abbreviations used are: CYP, cytochrome P450 enzyme; uPA, urokinase-type plasminogen activator; SCID, severe combined immunodeficient; hAlb, human albumin; RI, replacement index; 3-MC, 3-methylcholanthrene; HPLC, high-performance liquid chromatography; COH, coumarin 7-hydroxylase activity; DICOH, diclofenac 4'-hydroxylase activity; DEXOH, dexamethasone 6-hydroxylase activity; MPOH, *S*-mephenytoin 4'-hydroxylase activity; TESOH, testosterone 6 β -hydroxylase activity.

DMD#2600

Abstract

The induction and inhibition of human cytochrome P450 enzymes (CYPs) are responsible for drug interactions clinically. Although the induction of CYPs is investigated using human hepatocytes in the drug development process, there are some disadvantages such as the decline of the enzyme activity during culture. In the present study, we examined the *in vivo* induction potency in chimeric mice with humanized liver, which was recently established in Japan to clarify whether this chimeric mouse model would be more suitable for human induction studies. Rifampicin and 3-methylcholanthrene (3-MC) were used *in vivo* as typical CYP inducers in the chimeric mice. The expression levels of human CYP3A4 mRNA and CYP3A4 protein and dexamethasone 6-hydroxylase activity, specific for human CYP3A4, were increased 8- to 22-fold, 3- to 10-fold, and 5- to 12-fold, respectively, by the treatment with rifampicin. In addition, the expression levels of human CYP1A2 mRNA and CYP1A2 protein were also increased 2- to 9-fold and 5-fold, respectively, by the treatment with 3-MC. Although other human CYPs are expressed in the chimeric mice, there were few effects by the treatment of rifampicin and 3-MC on the mRNA, protein, and enzyme activity of those CYPs. It was demonstrated that human CYPs expressed in the chimeric mice with humanized liver were induced by rifampicin and 3-MC. This chimeric mouse model may be a useful animal model to estimate and predict the *in vivo* induction of CYPs in humans.

DMD#2600

Introduction

Studies of drug metabolism are important for the determination of pharmacokinetic behavior and interindividual variability. Cytochrome P450 enzymes (CYPs) play a central role in the oxidative, peroxidative, and reductive metabolism of numerous endogenous compounds as well as drugs, environmental chemicals, and pollutants (Li et al., 1995). CYP3A4 is the predominant isoform in human liver and small intestine (Shimada et al., 1994; Ding and Kaminsky, 2003), and is responsible for the metabolism of many clinical drugs (Li et al., 1995). In clinical practice, serious drug interactions are frequently caused by the induction and inhibition of CYPs (Dresser et al., 2000; Niemi et al., 2003). Induction is a long-term consequence of chemical exposure, whereas inhibition is an acute decrease of metabolism by another drug or a time-dependent decrease in the amount of an enzyme by several factors (Pelkonen et al., 1998). Therefore, the prediction of drug interactions involving CYPs is essential during drug development.

Recently, human hepatocytes, human liver microsomes, and recombinant human CYP microsomes have become available as enzyme sources for in vitro experimental systems. The major limitation of microsomes is that they cannot be used for induction studies, while the limitation of in vivo studies using experimental animals is the existence of species differences. Human hepatocytes in primary culture are considered to be the most suitable model for induction studies, but also have some problems such as the inability to proliferate, the quick degradation of CYP activities during culture, and the requirement for specific culturing or technical conditions (Li et al., 1997). On the other hand, a transgenic mouse model containing human CYP was generated (Corchero et al., 2001; Robertson et al., 2003; Zhang et al., 2003). These transgenic mice were mainly used for studying transcriptional regulation. Thus, the development of a better model of the human liver is needed.

DMD#2600

Recently, the generation of chimeric mice with humanized liver by the transplantation of human hepatocytes has been attempted (Dandri et al., 2001; Mercer et al., 2001). Using the urokinase-type plasminogen activator (uPA)/SCID mice, Tateno et al. (2004) succeeded in establishing chimeric mice whose livers could be replaced by more than 80% with human hepatocytes. At present, there are no reports of chimeric mice with as high a percentage of human hepatocytes as that reported by Tateno et al. (2004).

In the livers of these chimeric mice, we investigated the expression of human CYPs (Katoh et al., 2004). In the present study, we investigated the *in vivo* induction of human CYPs by the treatment of these chimeric mice with some model CYP inducers (rifampicin and 3-MC). When we discuss the induction of CYP, it is controversial whether the mRNA, protein, or enzyme activity is optimal to evaluate the induction. Roymans et al. (2004) reported that the induction ratios of CYP3A4 mRNA and testosterone 6 β -hydroxylase activity by rifampicin in human hepatocytes #QKR were greater than those in human hepatocytes #130, but the induction ratios of CYP3A4 protein were almost the same. On the other hand, Nallani et al. (2004) have reported that there was a significant correlation between CYP3A4 protein and the testosterone 6 β -hydroxylase activity as well as between CYP3A4 protein and its mRNA after paclitaxel treatment using human hepatocytes. In induction studies using human hepatocytes or animals, some reports showed only the expression levels of mRNA, but others showed the protein or the enzyme activity. In the present study, we measured the changes of mRNA, protein, and enzyme activity.

Primarily, the changes of hepatic CYPs needed to be evaluated because the induction of human CYPs in the livers of the chimeric mice led to changes in the pharmacokinetics of the drugs. Therefore, we measured the mRNA, protein, and enzyme activity in the liver of the chimeric mice after rifampicin and 3-MC treatment.

DMD#2600

Materials and Methods

Materials. All primers shown in Table 1 were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). Polyclonal rabbit anti-human CYP1A2 antibody, polyclonal rabbit anti-human CYP2A6 antibody, and polyclonal rabbit anti-human CYP2C8 antibody were purchased from Nosan (Yokohama, Japan). Polyclonal rabbit anti-human CYP1A1 was purchased from Chemicon (Temecula, CA). Polyclonal rabbit anti-human CYP2C9 antibody, monoclonal anti-human CYP2D6 antibody, and polyclonal rabbit anti-human CYP3A4 antibody were from BD Gentest (Worburn, MA). Pooled human liver microsomes and recombinant human CYP1A1, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, and CYP3A4 expressed in baculovirus-infected insect cells were also from BD Gentest. Diclofenac and 3-methylcholanthrene (3-MC) were purchased from Sigma-Aldrich (St. Louis, MO). Coumarin, 7-hydroxycoumarin, dexamethasone, and rifampicin were purchased from Wako Pure Chemical Industries (Osaka, Japan). *S*-Mephenytoin and (\pm)-4'-hydroxymephenytoin were obtained from Toronto Research Chemicals (Toronto, Canada) and Ultrafine Chemicals (Manchester, UK), respectively. 4'-Hydroxydiclofenac was purchased from BD Gentest. Nicotinamide adenine dinucleotide phosphate (oxidized form, NADP⁺) and glucose-6-phosphate dehydrogenase were purchased from Oriental Yeast (Tokyo, Japan). Nafamostat mesilate was kindly provided by Torii Pharmaceutical (Tokyo, Japan). All other chemicals and solvents were of the highest grade commercially available.

Generation of the Chimeric Mice with Humanized Liver. The present study was approved by the Ethics Committees of Kanazawa University and the Hiroshima Prefectural Institute of Industrial Science and Technology Ethics Board. The cryopreserved human hepatocytes from donor A (Caucasian, male, 9 months old) were purchased from In Vitro Technologies (Catonsville, MD). The human liver sample from donor B (Japanese, male, 12 years old) was

DMD#2600

obtained at autopsy after receiving written informed assent. The chimeric mice with humanized liver were generated by the method described previously (Tateno et al., 2004). Briefly, uPA^{+/+}/SCID mice at 20 to 30 days after birth were injected with human hepatocytes through a small left-flank incision into the inferior splenic pole. When necessary, the chimeric mice were treated intraperitoneally with nafamostat mesilate. The role of nafamostat mesilate was to prolong survival and promote steady gains in body weight within the 2 months after transplantation, because the chimeric mice die due to complement-induced disorders in organs other than the liver (Tateno et al., 2004). The concentration of human albumin (hAlb) in the blood of the chimeric mice and the replacement index (RI, the rate of the replacement from mice to humans) were measured using ELISA and anti-human specific cytokeratin 8 and 18 antibody, respectively. There was a good correlation between the hAlb concentration and the RI (Tateno et al., 2004). The male chimeric mice used in this study were 11-14 weeks old (Table 2). The uPA^{+/+}/SCID mice, uPA^{+/-}/SCID mice, and uPA^{-/-}/SCID mice were obtained as previously reported (Tateno et al., 2004).

Animal Treatments. The chimeric mice, uPA^{+/-}/SCID mice, and uPA^{-/-}/SCID mice were intraperitoneally treated daily for 4 days with rifampicin (50 mg/kg/day) or 3-MC (20 mg/kg/day). The mice used in the present study are listed in Tables 2 and 3.

Hepatic RNA Extraction and Real-time Reverse Transcription-PCR. Human CYP mRNA was quantified by real-time reverse transcription-PCR. Total hepatic RNA was extracted using ISOGEN (Nippon Gene, Tokyo, Japan) and cDNAs were synthesized as described previously (Iwanari et al., 2002). The sequences of primers that were specific to each human CYP are shown in Table 1. PCR was performed using the Smart Cycler (Cepheid, Sunnyvale, CA) with Smart Cycler software (Ver. 1.2b). The PCR conditions were as follows: after an initial denaturation at 95°C for 30 sec, amplification was performed by denaturation at 94°C for 4 sec, annealing and extension at 64°C for 20 sec for 45 cycles.

DMD#2600

Amplified products were monitored directly by measuring the increase of the dye intensity of the SYBR Green I (Molecular Probes, Eugene, OR) that binds to double strand DNA amplified by PCR. The copy number of mRNA in the cDNA samples was calculated using standard amplification curves. It was confirmed that the primer for human CYPs used in this study did not cross-react with murine Cyp mRNA.

Liver Microsomes. Liver microsomes from the chimeric or control mice were prepared as described previously (Yamazaki et al., 1999) and were stored at -80°C until analysis. The protein concentration was determined using Bradford protein assay reagent (Bio-Rad, Hercules, CA) with bovine gamma globulin as the standard.

Immunoblot Analysis of human CYP isoforms. SDS-PAGE and immunoblot analysis of human CYP1A1, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, and CYP3A4 were performed according to Leammler (1970) with slight modifications. The liver microsomes were separated on 7.5% polyacrylamide gel and transferred electrophoretically to a polyvinylidene di-fluoride membrane. Recombinant human CYPs were also applied as the standards. Biotinylated anti-rabbit or mouse IgG and a VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA) were used for diaminobenzidine staining.

Enzyme Assays. The typical incubation mixtures (total volume of 0.20 ml) consisted of microsomes in 100 mM potassium phosphate buffer (pH 7.4) containing an NADPH-generating system (0.5 mM NADP⁺, 5 mM glucose-6-phosphate, 5 mM MgCl₂, and 1 U/ml glucose-6-phosphate dehydrogenase) and a substrate. Coumarin 7-hydroxylase activity (COH) catalyzed by CYP2A6 was measured as described previously (Katoh et al., 2004). In brief, the concentrations of microsomes and coumarin were 0.1 mg/ml and 1 μM, respectively. The reaction mixture was incubated for 3 min at 37°C. The product formation was determined using high-performance liquid chromatography (HPLC) with a C₁₈ 5-μm analytical column (4.6 x 150 mm). Diclofenac 4'-hydroxylase activity (DICOH) catalyzed by

DMD#2600

CYP2C9 was determined as described previously (Katoh et al., 2004). The concentrations of microsomes and diclofenac were 0.2 mg/ml and 30 μ M, respectively. The reaction mixture was incubated for 30 min at 37°C. The mobile phase was 22% acetonitrile in 50 mM phosphate buffer (pH 7.4). The product formation was determined using HPLC with a C₁₈ 5- μ m analytical column (4.6 x 150 mm). *S*-Mephenytoin 4'-hydroxylase activity (MPOH) catalyzed by CYP2C19 was measured as described previously (Katoh et al., 2004). The concentrations of microsomes and *S*-mephenytoin were 0.2 mg/ml and 200 μ M, respectively. The reaction mixture was incubated for 30 min at 37°C. The product formation was determined using HPLC with a C₁₈ 5- μ m analytical column (4.6 x 150 mm). The eluent was monitored at 204 nm with a noise-base clean Uni-3 (Union, Gunma, Japan). The mobile phase was 18% acetonitrile in 50 mM potassium dihydrogen phosphate. Dexamethasone 6-hydroxylase activity (DEXOH) catalyzed by CYP3A4 was examined according to the method described previously (Katoh et al., 2004). The concentrations of microsomes and dexamethasone were 0.2 mg/ml and 100 μ M, respectively. The reaction mixture was incubated for 30 min at 37°C. The product formation was determined using HPLC with a C₈ 5- μ m analytical column (4.6 x 150 mm). The mobile phase was 22% acetonitrile : 0.018% formic acid = 18 : 82 (v/v). The eluent was monitored at 243 nm with a Uni-3. DEXOH was quantified using a standard curve of dexamethasone because we could not obtain authentic 6-hydroxydexamethasone. The retention time of 6-hydroxydexamethasone was confirmed using the incubation product of recombinant CYP3A4 and dexamethasone. The final concentration of the solvent in the incubation mixture was <1%. Data were analyzed using the mean of duplicate determinations.

Effect of Nafamostat Mesilate of Human CYP on Induction by Rifampicin or 3-MC in Chimeric Mice. To investigate the effect of nafamostat mesilate of human CYP on the induction by rifampicin or 3-MC, the induction of human CYP was compared between

DMD#2600

chimeric mice treated with and without nafamostat mesilate. The chimeric mice without nafamostat mesilate were not treated from 3 days before the start of the inducer treatment to the last day of this study.

Results

Chimeric mice used in the present study. Ten and four chimeric mice generated using hepatocytes from donor A and donor B were used in the present study (Table 2). The hAlb concentration, approximate RI, and inducer are shown in Table 2. The albumin concentration in the chimeric mice was measured one day before starting the inducer treatment. We confirmed that the expression of all hepatic mRNA and all enzyme activities in uPA^{+/-}/SCID mice and uPA^{-/-}/SCID mice were not affected by the administration of nafamostat mesilate (data not shown). To investigate the induction of CYPs, the expression levels of CYP mRNA and the protein content and the enzyme activity in a chimeric mouse were compared to those in a chimeric mouse with a similar hAlb concentration or RI. The expression levels of human GAPDH (hGAPDH) mRNA were increased in a hAlb concentration-dependent manner without the effect of inducers (data not shown).

Selectivity of Human CYP Antibodies to Human Microsomes in Immunoblot Analysis.

The selectivities of human CYP antibodies, especially human CYP3A4 (Fig. 1A) and human CYP1A2 (Fig. 1B), were investigated. The amounts of microsomal protein used in those immunoblot analyses, which were determined not to cross-react with the autologous murine Cyp proteins using induced murine liver microsomes, were as follows: CYP1A2, 10 µg (none treatment) and 1 µg (3-MC treatment); CYP2A6, 20 µg; CYP2C9, 5 µg; CYP3A4, 10 µg (none treatment) and 2 µg (rifampicin treatment). Human CYP1A1 antibodies were raised against a C-terminal peptide of human CYP1A1 and did not cross-react with induced murine

DMD#2600

liver microsomes (data not shown).

Induction of Human CYP3A4 in Rifampicin-treated Chimeric Mice. The effects of rifampicin treatment on CYP3A4 expression are shown in Fig. 2. The CYP3A4/hGAPDH mRNA ratios in rifampicin-treated chimeric mice with hepatocytes from donor A and donor B were 8.2- and 22.1-fold higher, respectively, than those in non-treated chimeric mice with similar concentrations of hAlb (Fig. 2A). The copy number of CYP3A4 mRNA was correlated with the hAlb concentration (Fig. 2B, None: $r = 0.77$; rifampicin: $r = 0.97$), and the slope of the fitted curve was increased in rifampicin-treated chimeric mice as compared with non-treated chimeric mice. The levels of CYP3A4 protein were increased 9.8-fold in the donor A chimeric mice and 3.0-fold in the donor B chimeric mice by the treatment with rifampicin (Fig. 2C). Rifampicin caused a significant enhancement of DEXOH in both the donor A chimeric mice (5.1- to 5.3-fold, mean: 5.2) and the donor B chimeric mice (10.0- to 14.6-fold, mean: 12.0), but no enhancement in uPA^{+/+}/SCID mice and uPA^{-/-}/SCID mice.

Changes of Human CYP2A6 Expression in Rifampicin-treated Chimeric Mice. The effects of rifampicin treatment on the CYP2A6 expression are shown in Fig. 3. The CYP2A6 mRNA, protein, and COH in the chimeric mice from donor B hepatocytes were not detected since these chimeric mice were genotyped as homozygous for the human *CYP2A6**4 allele (Kato et al., 2004), which deletes the whole human *CYP2A6* gene. The CYP2A6/hGAPDH mRNA ratios in rifampicin-treated chimeric mice with hepatocytes from donor A were 1.7-fold higher than those in non-treated chimeric mice with similar concentrations of hAlb (Fig. 3A). The CYP2A6 protein and COH were increased 3.5- and 2.4-fold by rifampicin treatment, respectively (Figs. 2B and 2C). There were no changes of COH caused by rifampicin treatment in either uPA^{+/+}/SCID mice or uPA^{-/-}/SCID mice.

Changes of Human CYP2C9 Expression in Rifampicin-treated Chimeric Mice. The effects of rifampicin treatment on CYP2C9 expression are shown in Fig. 4. The

DMD#2600

CYP2C9/hGAPDH mRNA ratio, the protein content, and DICOH in rifampicin-treated chimeric mice with hepatocytes from donor B were 22.1-, 1.3-, and 1.8- fold higher, respectively, than those in non-treated chimeric mice with similar concentrations of hAlb (Fig. 4). On the other hand, the chimeric mice with hepatocytes from donor A did not exhibit evidence of the induction. No changes of DICOH were caused by rifampicin treatment in either uPA^{+/+}/SCID mice or uPA^{-/-}/SCID mice.

Changes of Human CYP2C19 Expression in Rifampicin-treated Chimeric Mice. The effects of rifampicin treatment on CYP2C19 expression are shown in Fig. 5. The CYP2C19/hGAPDH mRNA ratios in rifampicin-treated chimeric mice with hepatocytes from donor A and donor B were higher than those in non-treated chimeric mice (Fig. 5A). The content of human CYP2C19 protein could not be quantified because no applicable primary antibodies are commercially available. There was not enough MPOH to calculate the induction ratio in the chimeric mice with donor B hepatocytes, but there was a 2.4-fold increase by rifampicin treatment in the chimeric mice with donor A hepatocytes (Fig. 5B). No changes in MPOH were caused by rifampicin treatment in either uPA^{+/+}/SCID mice or uPA^{-/-}/SCID mice.

Changes of Other Human CYPs in Rifampicin-treated Chimeric Mice. The mRNA and protein expressions of human CYP1A2 and CYP2D6 were not affected by treatment with rifampicin. The expression levels of human CYP2C8 mRNA in rifampicin-treated chimeric mice were 1.4- to 3.7-fold higher than those in non-treated chimeric mice. Similarly, the expression of human CYP2C8 protein was increased 1.6- to 2.5-fold by rifampicin (data not shown).

Induction of Human CYP1A2 Expression in 3-MC-treated Chimeric Mice. The effects of 3-MC treatment on human CYP1A2 (hCYP1A2) expression are shown in Fig. 6. The hCYP1A2/hGAPDH mRNA ratios in 3-MC-treated chimeric mice were 2.1- to 8.6-fold

DMD#2600

higher than those in non-treated chimeric mice (Fig. 6A). The slope of the fitted curve of human CYP1A2 mRNA was increased in 3-MC-treated chimeric mice as compared with non-treated chimeric mice (Fig. 6B, None: $r = 0.86$; 3-MC: $r = 0.96$). The 3-MC treatment increased the content of human CYP1A2 protein by 4.9-fold (3.6-6.4) in the donor A chimeric mice (Fig. 6C). Because of the lack of a substrate with specificity to human CYP1A2 that does not cross-react with murine Cyp1a, the induction of human CYP1A2 activity in the chimeric mice could not be evaluated.

Changes of Human CYP1A1 Expression in 3-MC-treated Chimeric Mice. The effects of 3-MC on human CYP1A1 (hCYP1A1) expression are shown in Fig. 7. The hCYP1A1/hGAPDH mRNA ratios were increased 18.7-fold (10.0-37.7) by 3-MC treatment (Fig. 7A). The slope of the fitted curve of human CYP1A1 mRNA was increased in 3-MC-treated chimeric mice as compared with non-treated chimeric mice (Fig. 7B, None: $r = 0.83$; 3-MC: $r = 0.82$). Human CYP1A1 proteins in both non- and 3-MC-treated chimeric mice were below 0.6 fmol/mg protein.

Changes of Other Human CYPs in Chimeric Mice. The changes of CYP3A4 protein, CYP2A6 protein, CYP2C9 protein, DEXOH, COH, DICOH, and MPOH by 3-MC treatment are shown in Fig. 8. The treatment with 3-MC did not affect those enzyme activities. Similarly, in both uPA^{+/+}/SCID mice and uPA^{-/-}/SCID mice, there were no changes in DEXOH, COH, DICOH, and MPOH by 3-MC treatment. The expression levels of mRNA and protein in CYP2C8 and CYP2D6 exhibited no changes by 3-MC treatment (data not shown).

Effect of Nafamostat Mesilate of Human CYP on Induction by Rifampicin or 3-MC in Chimeric Mice. In the induction study of rifampicin, the induction of DEXOH was 38.7, 43.7, and 59.2 pmol/mg protein/min in chimeric mice No.11, 12, and 13, respectively, which were treated with both rifampicin and nafamostat mesilate (Fig. 3D). In the chimeric mice

DMD#2600

treated with rifampicin but not with nafamostat mesilate, DEXOH was 34.1 (hAlb concentration = 5.0 mg/ml), 43.3 (hAlb concentration = 7.6 mg/ml), and 45.8 (hAlb concentration = 9.6 mg/ml) pmol/mg protein/min. On the other hand, in the induction study of 3-MC, the expression levels of human CYP1A2 protein were 13.7, 17.9, and 17.8 pmol/mg protein in chimeric mice No. 22, 23, and 24, respectively (Fig. 6C). In the chimeric mice treated with 3-MC but not with nafamostat mesilate, the expression levels of human CYP1A2 protein were 10.6 (hAlb concentration = 5.1 mg/ml), 17.0 (hAlb concentration = 7.6 mg/ml), and 20.0 pmol/mg protein (hAlb concentration = 9.9 mg/ml). Nafamostat mesilate treatment caused no significant differences in the induction of DEXOH by rifampicin and CYP1A2 protein by 3-MC.

Discussion

The induction and inhibition of CYP enzymes are considered to cause many drug interactions. In the drug development process, it is extremely important to investigate whether a drug candidate will be an inducer or an inhibitor of CYPs in order to predict potential drug interactions in humans (Lin and Lu, 2001). The induction of CYP is defined as an increase in CYP activity associated with an increase in the intracellular CYP concentration (Ronis and Ingelman-Sundberg, 1999). At present, the inhibition of CYPs in humans can be predicted relatively easily from *in vitro* approaches using recombinant human CYPs and/or human liver microsomes. However, the results of CYP induction studies obtained from experimental animals are difficult to extrapolate to humans due to species differences. Primary cultured human hepatocytes are considered to be a more appropriate tool for the evaluation of the induction in humans. However, it has been reported that CYP mRNA in human hepatocytes declined rapidly after the isolation from liver (Gómez-Lechón et al., 2003). Moreover, the

DMD#2600

supply of human hepatocytes is sometimes limited.

Recently, chimeric mice with humanized liver were established by Tateno et al. (2004). The livers of the mice could be replaced by more than 80% with human hepatocytes. We clarified that major human CYPs were expressed in such livers and that the enzyme activities were almost the same as those of the donor (Katoh et al., 2004). In this study, we investigated the induction potency of human CYPs in chimeric mice with humanized liver to determine whether the chimeric mice can be a useful tool in studies of human CYP induction.

There are many drug interactions with rifampicin caused by the induction of drug metabolizing enzymes such as CYP3A4 (Niemi et al., 2003). It has been reported that the exposure of human hepatocytes to rifampicin caused an approximately 10- and 5-fold increase in the expression levels of CYP3A4 mRNA and the protein content, respectively (Drocourt et al., 2001; Desai et al., 2002; Raucy et al., 2002). The induction effects of rifampicin on testosterone 6 β -hydroxylase activity (TESOH) catalyzed by CYP3A4 in human hepatocytes averaged 10-fold compared to the control, but large interindividual differences were reported (Desai et al., 2002; Madan et al., 2003). In the present study, rifampicin significantly induced CYP3A4 mRNA (8.2-fold in the donor A chimeric mice and 22.1-fold in the donor B chimeric mice) and increased the protein content (9.8- and 3.0-fold) and DEXOH (5.2- and 12.0-fold), in a manner consistent with previous reports. As we described, it is not always the case that the induction between the mRNA, protein, and enzyme activity can be correlated. This point is still controversial concerning both constitutive and inducible expression. This phenomenon is observed not only in chimeric mice but also in human hepatocytes.

Rifampicin induced CYP3A4 protein but not CYP3A5 protein in human hepatocytes (Schuetz et al., 1993). Since both donors in this study were genotyped as homozygous for the *CYP3A5**3 allele (Katoh et al., 2004), further studies using chimeric mice generated from

DMD#2600

various donors are needed to clarify the induction of CYP3A5.

Rifampicin moderately induced murine Cyp3a11 mRNA and Cyp3a protein at a dose of 50 to 100 mg/kg/day for 2 to 4 days (Yanagimoto et al., 1997; Schuetz et al., 2000). TESOH is catalyzed by Cyp3a in mice. TESOH in uPA^{+/-}/SCID mice was not changed by rifampicin treatment, whereas it was increased 2.4-fold in uPA^{-/-}/SCID compared to the control ($P < 0.01$, data not shown), suggesting that rifampicin weakly induced Cyp3a. In both uPA^{+/-}/SCID mice and uPA^{-/-}/SCID mice, rifampicin had no effect on DEXOH, indicating that DEXOH was specific to human CYP3A but not to murine Cyp3a (Tomlinson et al., 1997).

Rifampicin also induces the mRNAs and proteins of CYP2C8, CYP2C9, and CYP2C19 in human hepatocytes (Gerbal-Chaloin et al., 2001; Raucy et al., 2002). On the other hand, it has been reported that there were no changes in CYP2C8 protein (Edwards et al., 2003), CYP2C9 protein (Runge et al., 2000; Edwards et al., 2003), and CYP2C19 protein (Runge et al., 2000) following treatment with rifampicin in human hepatocytes or human liver slices. In addition, Raucy et al. (2002) described that the induction of CYP2C8 protein exhibited large interindividual variability, and HH954 hepatocytes in their report failed to respond to rifampicin treatment. They also reported that the induction of CYP2C19 protein exhibited large interindividual differences (5.7 ± 5.3 fold) (Raucy et al., 2002). In clinical practice, rifampicin may induce CYP2C-mediated metabolism and thus reduce the plasma concentration of CYP2C9 substrates such as warfarin and sulfonylurea antidiabetic drugs (Niemi et al., 2003). In the present study, rifampicin tended to cause a slight increase in CYP2C8 protein, CYP2C9 protein, DICOH catalyzed by CYP2C9, and MPOH catalyzed by CYP2C19, and showed interindividual differences. In the case of CYP2C19, it was difficult to estimate the induction, because the MPOH in the donor B chimeric mice was lower. The donor B chimeric mice were genotyped as *CYP2C19*1/CYP2C19*2* (Katoh et al., 2004), which would lead to a reduction of the enzyme activity (Bramness et al., 2003). In this study,

DMD#2600

the calculated induction ratio is an apparent value, since the human albumin concentrations are similar but not the same between non- and inducer-treated chimeric mice. Further investigations will be needed to clarify the induction potency by rifampicin of CYP2Cs in chimeric mice.

In relation to human CYP2A6, some in vitro reports using human liver slices and human hepatocytes exhibited the induction of CYP2A6 protein and COH by rifampicin treatment, respectively (Edwards et al., 2003; Madan et al., 2003). However, another study that used human hepatocytes showed no change in CYP2A6 mRNA and COH (Donato et al., 2000). Ethoxyresorufin *O*-dealkylase activity catalyzed by CYP1A2 was increased by treatment with rifampicin in human hepatocytes (Madan et al., 2003). In CYP1A2 and CYP2A6, rifampicin increased the mRNA, protein content, and enzyme activity 3-fold at most compared with the control (Edwards et al., 2003; Madan et al., 2003). Therefore, these results did not contradict those of the present study.

Following the exposure of 3-MC, human CYP1A2 protein and ethoxyresorufin *O*-dealkylase activities were increased in human hepatocytes, leading to the induction of CYP1A2 in humans (Donato et al., 1995; Runge et al., 2000). In the present study, human CYP1A2 mRNA and protein were induced by treatment with 3-MC in the chimeric mice, which was consistent with previous reports (Donato et al., 1995; Runge et al., 2000). 3-MC significantly increased the expression levels of human CYP1A1 mRNA in the present study. The CYP1A1 antibodies used in this study were very sensitive and could detect 25 fmol of the recombinant human CYP1A1, but the pooled human liver microsomes from BD Gentest did not show the band (data not shown). CYP1A1 is known as an isoform with low expression in normal human liver (Turesky et al., 1998). CYP1A1 protein in both non- and 3-MC-treated chimeric mice could not be detected. CYP1A1 protein in the liver of donor A may have been very low, therefore, human CYP1A1 proteins in the donor A chimeric mice

DMD#2600

could not be detected although human CYP1A1 mRNA could be detected.

There appeared to be some variability in the responses to these inducers in terms of the mRNA, protein, and enzyme activity. The difference is thought to be due to the interindividual variability of the chimeric mice, but the reasons are still unclear. We think that such variability could be overcome by increasing the number of the chimeric mice, because it was also observed in studies using human hepatocytes.

As described above, it was demonstrated that CYP enzymes were induced in the chimeric mice with humanized liver. The expression of each murine Cyp mRNA in chimeric mouse No. 3, which exhibited the highest hAlb concentration in this study, was no more than 5% compared to that in uPA^{+/+}/SCID mice (data not shown). It was surmised that human CYPs in the chimeric mice were induced by rifampicin or 3-MC treatment, but further study is needed to clarify the expression of human nuclear receptors and the transcriptional regulation mechanism in the chimeric mice.

In conclusion, human CYPs expressed in chimeric mice with humanized liver respond to induction via treatment with rifampicin and 3-MC. At present, human hepatocytes are still a better model for investigating the induction of CYPs, but the number of human hepatocytes that can be obtained from one donor may not be sufficient for the experimental purposes and frequently none can be obtained at all. Using these chimeric mice, human hepatocytes could be made to proliferate easily at low cost. In some countries including Japan, large amounts of human organ materials such as hepatocytes and microsomes are very difficult to obtain. In such cases, the lack of a stable supply of human liver is a serious problem. One of the advantages of the chimeric mice is that they could be used to proliferate human hepatocytes. In addition, this chimeric mouse line would be a better tool than any other experimental animal for estimating the *in vivo* induction potency in humans. It would be of interest to measure the pharmacokinetics of drugs in chimeric mice treated with a typical CYP inducer.

DMD#2600

This chimeric mouse line could be more useful than human hepatocytes for estimating the pharmacokinetics and drug metabolism in humans. We hope that this study will greatly contribute to future advances in studies of drug metabolism as well as drug development.

Acknowledgment

We acknowledge Mr. Brent Bell for reviewing the manuscript.

DMD#2600

References

- Bramness JG, Skurtveit S, Fauske L, Grung M, Molven A, Morland J and Steen VM (2003) Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? *Pharmacogenetics* 13:383-388.
- Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR and Gonzalez FJ (2001) The *CYP2D6* humanized mouse: effect of the human *CYP2D6* transgene and HNF4alpha on the disposition of debrisoquine in the mouse. *Mol Pharmacol* 60:1260-1267.
- Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, Greten H and Petersen J (2001) Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. *Hepatology* 33:981-988.
- Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ and Buckley AR (2002) Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. *Drug Metab Dispos* 30:608-612.
- Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. *Annu Rev Pharmacol Toxicol* 43:149-173.
- Donato MT, Castell JV and Gómez-Lechón MJ (1995) Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. *Drug Metab Dispos* 23:553-558.
- Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, Raunio H,

DMD#2600

- Gómez-Lechón MJ and Pelkonen O (2000) CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. *Drug Metab Dispos* 28:1321-1326.
- Dresser GK, Spence JD and Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clin Pharmacokinet* 38:41-57.
- Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P and Vilarem MJ (2001) Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. *Drug Metab Dispos* 29:1325-1331.
- Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR and Lake BG (2003) Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. *Drug Metab Dispos* 31:282-288.
- Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. *Drug Metab Dispos* 29:242-251.
- Gómez-Lechón MJ, Donato MT, Castell JV and Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. *Curr Drug Metab* 4:292-312.
- Iwanari M, Nakajima M, Kizu R, Hayakawa K and Yokoi T (2002) Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. *Arch Toxicol* 76:287-298.
- Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K and Yokoi T (2004) Expression of human CYPs in chimeric mice with humanized liver, *Drug Metab Dispos* 32:1402-1410.

DMD#2600

Klose TS, Blaisdell JA and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. *J Biochem Mol Toxicol* 13:289-295.

Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680-685.

Li AP, Kaminski DL and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. *Toxicology* 104:1-8.

Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC and Jurima-Romet M (1997) Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. *Chem Biol Interact* 107:5-16.

Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. *Annu Rev Pharmacol Toxicol* 41:535-567.

Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L and Parkinson A (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. *Drug Metab Dispos* 31:421-431.

Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL and Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. *Nat Med* 7:927-933.

Nallani SC, Goodwin B, Buckley AR, Buckley DJ and Desai PB (2004) Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. *Cancer Chemother Pharmacol* 54:219-229.

Niemi M, Backman JT, Fromm MF, Neuvonen PJ and Kivisto KT (2003) Pharmacokinetic

DMD#2600

- interactions with rifampicin: clinical relevance. *Clin Pharmacokinet* 42:819-850.
- Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A and Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. *Xenobiotica* 28:1203-1253.
- Raucy JL, Mueller L, Duan K, Allen SW, Strom S and Lasker JM (2002) Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. *J Pharmacol Exp Ther* 302:475-482.
- Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A and Liddle C (2003) Transgenic mouse models of human *CYP3A4* gene regulation. *Mol Pharmacol* 64:42-50.
- Ronis MJJ and Ingelman-Sundberg M (1999) Induction of human drug metabolizing enzymes: mechanisms and implications, in *Handbook of Drug Metabolism* (Woolf ed) pp 239-262, Marcel Dekker, New York.
- Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G and Meuldermans W (2004) Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. *Biochem Pharmacol* 67:427-437.
- Runge D, Kohler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE and Michalopoulos GK (2000) Induction of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. *Biochem Biophys Res Commun* 273:333-341.
- Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D and Guzelian PS (1993) Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. *Hepatology* 18:1254-1262.

DMD#2600

Schuetz EG, Schmid W, Schutz G, Brimer C, Yasuda K, Kamataki T, Bornheim L, Myles K and Cole TJ (2000) The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver. *Drug Metab Dispos* 283:268-278.

Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 270:414-423.

Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa Y and Yoshizato K (2004) Near-completely humanized liver in mice shows human-type metabolic responses to drugs. *Am J Pathol*, 165:901-912.

Tomlinson ES, Maggs JL, Park BK and Back DJ (1997) Dexamethasone metabolism in vitro: species differences. *J Steroid Biochem Mol Biol* 62:345-352.

Turesky RJ, Constable A, Richoz J, Varga N, Markovic J, Martin MV and Guengerich FP (1998) Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2. *Chem Res Toxicol* 11:925-936.

Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP and Yokoi T (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. *Drug Metab Dispos* 27:1260-1266.

Yanagimoto T, Itoh S, Sawada M and Kamataki T (1997) Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B₁. *Arch Biochem Biophys* 340:215-218.

Zhang W, Purchio AF, Chen K, Wu J, Lu L, Coffee R, Contag PR and West DB (2003) A

DMD#2600

transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene. *Drug Metab Dispos* 31:1054-1064.

DMD#2600

FOOTNOTES

This work was supported by Research on Advanced Medical Technology, Health, and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan.

To whom correspondence should be addressed to Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Tel / Fax: +81-76-234-4407, E-mail: TYOKOI@kenroku.kanazawa-u.ac.jp

DMD#2600

Figure legends

Fig. 1. Selectivity of human CYP antibodies to human CYP on immunoblot analysis.

Immunoblot analyses of microsomes from pooled human liver, an induced chimeric mouse, and an induced uPA^{+/-}/SCID mouse were performed using human CYP 3A4 antibodies (A) and human CYP1A2 antibodies (B). A, The lanes of human liver microsomes (H) and chimeric mouse No. 3 were 10 µg and the lanes of chimeric mouse No. 13 and M2 and M5 were 2 µg. The recombinant human CYP3A4 from BD Gentest (0.2, 0.7, and 0.9 pmol) was used as a standard. B., The lanes of H and chimeric mouse No. 3 were 10 µg and the lanes of chimeric mouse No. 24 and M3 and M6 were 1 µg. The recombinant human CYP1A2 from BD Gentest (25, 50, 100, 200 fmol) was used as a standard. M2: Rifampicin-treated uPA^{+/-}/SCID mouse; M3: 3-MC-treated uPA^{+/-}/SCID mouse; M4: Rifampicin-treated uPA^{-/-}/SCID mouse; M5: R3-MC-treated uPA^{-/-}/SCID mouse.

Fig. 2. Induction of human CYP3A4 expression in rifampicin-treated chimeric mice.

Hepatic CYP3A4 mRNAs in the chimeric mice were measured by real-time PCR (A and B). The CYP3A4 mRNA was expressed as the relative expression to hGAPDH (A, CYP3A4/hGAPDH) and the copy number (B, arbitrary unit). The CYP3A4 protein content (C) and dexamethasone 6-hydroxylase activity (DEXOH) catalyzed by CYP3A4 (D) were determined by Western bolt analysis and HPLC, respectively. A, C and D, Open column and closed column are expressed values of the non- and rifampicin-treated chimeric mice, respectively. B, Circle and triangle represent the chimeric mice with hepatocytes from donor A and from donor B, respectively. The open symbol and closed symbol represent non- and rifampicin-treated chimeric mice, respectively. D, The columns of M1, M2, M4, and M5 represent the mean ± SD (n=3). None: Non-treated; Rif: Rifampicin-treated; M1: Non-treated

DMD#2600

uPA^{+/+}/SCID mouse; M2: Rifampicin-treated uPA^{+/+}/SCID mouse; M4: Non-treated uPA^{-/-}/SCID mouse; M5: Rifampicin-treated uPA^{-/-}/SCID mouse.

Fig. 3. Changes of human CYP2A6 expression in rifampicin-treated chimeric mice.

Hepatic CYP2A6 mRNAs in the chimeric mice measured by real-time PCR were expressed as the relative expression to hGAPDH (A, CYP2A6/hGAPDH). The CYP2A6 protein content (B) and coumarin 7-hydroxylase activity (COH) catalyzed by CYP2A6 (C) were determined by Western bolt analysis and HPLC, respectively. The open column and closed column are the values of the non- and rifampicin-treated chimeric mice, respectively. C, The columns of M1, M2, M4, and M5 represent the mean \pm SD (n=3). ND: Not detected; M1: Non-treated uPA^{+/+}/SCID mouse; M2: Rifampicin-treated uPA^{+/+}/SCID mouse; M4: Non-treated uPA^{-/-}/SCID mouse; M5: Rifampicin-treated uPA^{-/-}/SCID mouse.

Fig. 4. Changes of human CYP2C9 expression in rifampicin-treated chimeric mice.

Hepatic CYP2C9 mRNAs in the chimeric mice measured by real-time PCR were expressed as the relative expression to hGAPDH (A, CYP2C9/hGAPDH). The CYP2C9 protein content (B) and diclofenac 4'-hydroxylase activity (DICOH) catalyzed by CYP2C9 (C) were determined by Western bolt analysis and HPLC, respectively. The open column and closed column are the values of the non- and rifampicin-treated chimeric mice, respectively. C, The columns of M1, M2, M4, and M5 represent the mean \pm SD (n=3). M1: Non-treated uPA^{+/+}/SCID mouse; M2: Rifampicin-treated uPA^{+/+}/SCID mouse; M4: Non-treated uPA^{-/-}/SCID mouse; M5: Rifampicin-treated uPA^{-/-}/SCID mouse.

Fig. 5. Changes of human CYP2C19 expression in rifampicin-treated chimeric mice.

Hepatic CYP2C19 mRNAs in the chimeric mice measured by real-time PCR were expressed

DMD#2600

as the relative expression to hGAPDH (A, CYP2C9/hGAPDH). The *S*-mephenytoin 4'-hydroxylase activity (MPOH) catalyzed by CYP2C19 (B) was determined by HPLC. The open column and closed column are the values of the non- and rifampicin-treated chimeric mice, respectively. B, The columns of M1, M2, M4, and M5 represent the mean \pm SD (n=3). ND: Not detected. M1: Non-treated uPA^{+/+}/SCID mouse; M2: Rifampicin-treated uPA^{+/+}/SCID mouse; M4: Non-treated uPA^{-/-}/SCID mouse; M5: Rifampicin-treated uPA^{-/-}/SCID mouse.

Fig. 6. Changes of human CYP1A2 expression in 3-MC-treated chimeric mice.

Hepatic human CYP1A2 mRNAs in the chimeric mice were measured by real-time PCR (A and B). The human CYP1A2 mRNA was expressed as the relative expression to human GAPDH (A, hCYP1A2/hGAPDH) and the copy number (B, arbitrary unit). The human CYP1A2 protein content (C) was determined by Western blot analysis. A and C, Open column and closed column are values of the non- and 3-MC-treated chimeric mice, respectively. None: Non-treated; Rif: Rifampicin-treated; ND: Not detected.

Fig. 7. Changes of human CYP1A1 expression in 3-MC-treated chimeric mice.

Hepatic human CYP1A1 mRNAs in the chimeric mice were measured by real-time PCR (A and B). The human CYP1A1 mRNA was expressed as the relative expression to human GAPDH (A, hCYP1A1/hGAPDH) and the copy number (B, arbitrary unit). A, Open column and closed column are the expressed values of the non- and 3-MC-treated chimeric mice, respectively. None: Non-treated; Rif: Rifampicin-treated.

Fig. 8. Changes of human CYP3A4, CYP2A6, CYP2C9, and CYP2C19 expressions in 3-MC-treated chimeric mice.

DMD#2600

Protein contents of human CYP3A4 (A), CYP2A6 (C) and CYP2C9 (E) in the chimeric mice were measured by Western blot analysis. The dexamethasone 6-hydroxylase activity (DEXOH) catalyzed by CYP3A4 (B), Coumarin 7-hydroxylase activity (COH) catalyzed by CYP2A6 (D), diclofenac 4'-hydroxylase activity (DICOH) by CYP2C9 (F), and *S*-mephenytoin 4'-hydroxylase activity (MPOH) by CYP2C19 (G) were determined by HPLC. The open column and closed column are the values of the non- and 3-MC-treated chimeric mice, respectively. B, D, F, and G, The columns of M1, M3, M4 and M6 represent the mean \pm SD (n=3). ND: Not detected. M1: Non-treated uPA^{+/+}/SCID mouse; M3: 3-MC-treated uPA^{+/+}/SCID mouse; M4: Non-treated uPA^{-/-}/SCID mouse; M6: 3-MC-treated uPA^{-/-}/SCID mouse.

DMD#2600

Table 1. Sequence of the primers used in the present study.

Primer	Sequence
CYP1A1 S	5'-ATGACCAGAAGCTATGGGTC-3'
CYP1A1 AS	5'-GCACGCTGAATTCCACCC-3'
CYP1A2 S	5'-GCTTCTACATCCCCAAGAAAT-3'
CYP1A2 AS	5'-TCCCCTTGGCCAGGACT-3'
CYP2A6 S	5'-AGCAACAGGCCTTTCAGTT-3'
CYP2A6 AS	5'-CCCAATGAAGAGGTTCAAC-3'
CYP2C8 S ^a	5'-AGATCAGAATTTTCTCACCC-3'
CYP2C8 AS ^a	5'-AACTTCGTGTAAGAGCAACA-3'
CYP2C9 S	5'-CAGATCTGCAATAATTTTCTC-3'
CYP2C9 AS	5'-CTTTCAATAGTAAATTCAGATG-3'
CYP2C19 S ^a	5'-ATTGAATGAAAACATCAGGATTG-3'
CYP2C19 AS ^a	5'-GAGGGTTGTTGATGTCCATC-3'
CYP2D6 S	5'-GGTGTGACCCATATGACATC-3'
CYP2D6 AS	5'-CTCCCCGAGGCATGCACG-3'
CYP3A4 S	5'-CCAAGCTATGCTCTTCACCG-3'
CYP3A4 AS	5'-TCAGGCTCCACTTACGGTGC-3'
hGAPDH S	5'-CCAGGGCTTTTAACTC-3'
hGAPDH AS	5'-GCTCCCCCTGCAAATGA-3'

S: sense primer; AS: anti-sense primer.

^aFrom Klose et al. (1999).

DMD#2600

Table 2. Chimeric mice used in the present study.

Mouse No.	Donor	hAlb ^a mg/ml	Approximate RI %	Inducer
1	A	2.1	60	None
2	A	9.3	70	None
3	A	13.7	90	None
4	B	3.5	60	None

11	A	4.2	60	Rifampicin
12	A	5.7	70	Rifampicin
13	A	11.4	80	Rifampicin
14	B	2.3	50	Rifampicin
15	B	4.2	50	Rifampicin
16	B	5.2	50	Rifampicin

21	A	2.2	70	3-MC
22	A	2.8	60	3-MC
23	A	4.6	80	3-MC
24	A	13.0	80	3-MC

A: Caucasian, male, 9 months old.

B: Japanese, male, 12 years old.


^a Human albumin concentration in chimeric mouse.


DMD#2600


Table 3. Control mice used in the present study.


Mouse No.	Strain	Inducer
M1	uPA ^{+/-} /SCID	None
M2	uPA ^{+/-} /SCID	Rifampicin
M3	uPA ^{+/-} /SCID	3-MC
.....		
M4	uPA ^{-/-} /SCID	None
M5	uPA ^{-/-} /SCID	Rifampicin
M6	uPA ^{-/-} /SCID	3-MC














Fig. 7.

DMD Fast Forward. Published on March 15, 2005 as DOI: 10.1124/dmd.104.002600
This article has not been copyedited and formatted. The final version may differ from this version.

